CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 117 enrolled
Drug / intervention
Genetic Sequencinggenetic
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02810327
NCT02810327N/ACompleted
CompareCT.gov

Alpha-1 Carrier Genomics Study

Medical University of South Carolina·observational·Posted Jun 22, 2016·Updated Jul 22, 2019

In Brief

An observational study evaluating Genetic Sequencing for Alpha-1 Antitrypsin Deficiency and 3 related conditions. Completed, enrolled 117 participants across 1 site.

Detailed Summary

The goal of this study is to better understand why some Alpha-1 genotype MZ (PiMZ) individuals develop chronic obstructive pulmonary disease (COPD) while others do not. This study will examine portions of the Alpha-1 gene that are not routinely tested to determine whether other changes in this gene correlate with development and progression of COPD. Participation involves responding to questionnaires about lung health and history, and performing an at-home finger stick to obtain blood spots using a test kit that is mailed. The blood provided will be used for genetic testing and correlation of results with COPD history. Participants will receive their results and access to genetic counseling at the conclusion of the study.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAlpha-1 Antitrypsin Deficiency, Emphysema, COPD, Smoking
CountriesUnited States
CollaboratorsCSL Behring

Timeline

N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedJun 22, 2016
Enrollment StartFeb 1, 2015
Primary CompletionApr 1, 2017
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 10.0 years ago

Interventions

Genetic Sequencinggenetic

Sequencing of the SERPINA1 gene